By E-Mail
April 2, 2019

To: The Office of the Vermont Attorney General
AGO.highcostprescriptiondrugs@vermont.gov

Notification of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

On January 15, 2019, the Food & Drug Administration (FDA) approved Cablivi (caplacizumab-yhdp) for the treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP). Ablynx NV, a Sanofi company (collectively referred to herein as "Sanofi"), manufactures Cablivi, which has a wholesale acquisition cost (WAC) that exceeds the threshold set for a specialty drug under the Medicare Part D program. Therefore, pursuant to 18 V.S.A. § 4637(b), Sanofi hereby provides written notice to the Office of the Attorney General that it introduced Cablivi to the commercial market on April 2, 2019, 2019. We have provided information about the new prescription drug in the grid below.

Manufacturer	Ablynx NV, a Sanofi company
Product Name	Cablivi (caplacizumab-yhdp)
NDC	*NDC 58468-0227-1*
Date of Introduction to Market	*April 2, 2019*

In providing this notice, Sanofi expressly reserves any and all rights or claims it may have with respect to 18 V.S.A. § 4637, the company's interpretation thereof, or the statute's application to Sanofi, Ablynx NV, or any other entity affiliated with or otherwise under the control of Sanofi.

Sincerely,

Phillip Ridolfi

Head of Business Operations and Support, Sales Support